Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Irene Robinson

  • Home
  • Author: Irene Robinson

COVID-19 response differs vastly between Presidential candidates

One of the most important topics for the upcoming presidential election in the US will be the next government’s response to the COVID-19 pandemic. COVID-19 testing started late and left the US unprepared for the initial wave. With an ongoing, even larger second wave oncoming, the US is seeing no sign of relief in sight at the beginning […]
Read more

Strong 52-week Mirikizumab Phase II data holds promise for Eli Lilly in Crohn’s disease

New data unveiled at the United European Gastroenterology Week (UEGW) virtual conference showed that Eli Lilly’s Crohn’s disease (CD) hopeful, mirikizumab, can deliver durable endoscopic and symptomatic efficacy after 52 weeks in moderate-to-severe patients who had failed or were intolerant to conventional therapy and had failed at least one other biologic agent. mirikizumab’s prospects are favorable in the […]
Read more

COVID-19 may prompt agreement on post-Brexit trade deal

With the world still grappling with the COVID-19-induced economic recession, the UK and the EU have another challenge to face – Brexit. Both sides will lose out economically in the event of no-deal, and the harder Brexit is the greater losses will be, says GlobalData a leading data and analytics company. Urte Jakimaviciute MSc, Senior Director of Market Research, comments: “The Brexit trade […]
Read more

Alkermes is expected to expand its presence in the schizophrenia market with its candidate ALKS-3831

Following the announcement of positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the FDA in support of Alkermes’ ALKS-3831 for the treatment of Schizophrenia and Bipolar I Disorder; Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and […]
Read more

Breast Cancer Screening Needs to Continue Despite COVID-19

October is Breast Cancer Awareness Month, a worldwide annual campaign that highlights the importance of breast cancer awareness, education and research. One of the consequences of COVID-19 is delays in health checks and preventative screening for cancer, which could result in a huge number of additional cancer casualties, if not managed correctly, says GlobalData, a leading data […]
Read more

Eli Lilly’s and Regeneron’s EUA applications for their COVID-19 mAb therapies short of clinically relevant data; clinical study participations hampered if process politicized

As US President Donald J. Trump puts his weight behind Eli Lilly and Regeneron Pharmaceuticals’ bid for an FDA Emergency Use Authorization (EUA) for their respective COVID-19 monoclonal antibody (mAb) therapies; Manasi Vaidya and Reynald Castañeda, Pharma Writers for the Investigative News team at GlobalData, offer their view: “Experts we interviewed emphasized the need for […]
Read more

Invokana may experience moderate rebound from decreasing US sales trend following FDA backtracking on boxed warning

The FDA has removed a boxed warning concerning the risk of leg and foot amputations for Janssen’s sodium glucose co-transporter (SGLT) inhibitor, Invokana (canagliflozin) – including its combination varieties Invokamet (canagliflozin + metformin) and Invokamet XR (canagliflozin + metformin extended-release). With the removal of the boxed warning, it is expected that Invokana will experience a […]
Read more

FDA and EMA designations for Acceleron’s Sotatercept highlight potential to differentiate in PAH space

Acceleron Pharma’s sotatercept, was granted priority designation by the European Medicines Agency for pulmonary arterial hypertension (PAH) in May 2020. This further signifies the drug’s major advantages over existing treatments, and will provide enhanced support for its development for targeting underlying disease progression in PAH, according to GlobalData, a leading data and analytics company. The […]
Read more

Price cap extension on knee implants will drive growth in India

To provide relief to patients undergoing orthopedic surgery requiring knee implants, the National Pharmaceutical Pricing Authority (NPPA) extended the timeline of price cap on these devices by one more year. The move is likely to drive the sale of knee implants in India, says GlobalData, a leading data and analytics company. GlobalData’s report Knee Reconstruction (Orthopedic Devices) – Global […]
Read more

Smith & Nephew strengthens presence in global orthopedic market with acquisition of Integra’s Extremity Orthopaedics business

Following the announcement that Smith & Nephew has acquired the Extremity Orthopaedics business of Integra LifeSciences for $240m; Kamilla Kan, Medical Devices Analyst at GlobalData, a leading data and analytics company, offers her view on this deal: “According to GlobalData, over 71% of Integra LifeSciences’ net sales are across business segments from North America. By […]
Read more

The growth of global insulin pen market decelerates to 2.3% in 2020 due to COVID-19

The insulin delivery market has been negatively affected by the major upheavals experienced in diabetic care due to COVID-19. The insulin pen market, which was seeing a compound annual growth rate (CAGR) of 5.1% prior to COVID-19, according to leading data and analytics company GlobalData, has now decreased to show 2.3% growth in 2020 due to new patient start delays from physician […]
Read more

Oral GnRH antagonists could have market potential in female health space beyond endometriosis-related pain and uterine fibroid indications

Oral GnRH antagonists have off-label potential in the female infertility space, beyond the indications of endometriosis-associated pain and uterine fibroids, which constitute the main development focus for companies competing in the space, says GlobalData, a leading data and analytics company. Due to their novel oral formulation, the company notes that GnRH antagonists could replace subcutaneous […]
Read more

Demand for US LNG is likely to remain depressed in the near future

Global economic slowdown has led to reduced demand for LNG produced in the US. As a result, LNG exports from the country are likely to remain low in the near future, says GlobalData, a leading data and analytics company. Haseeb Ahmed, Oil and Gas Analyst at GlobalData, comments: “Significantly low prices of gas along with an LNG supply glut has pushed companies to revisit their capex spends on upcoming multi-billion-dollar gas projects. In March 2020, Royal Dutch Shell exited the proposed Lake Charles LNG export project in Louisiana. […]
Read more
1 … 7 8 9 10 11 … 15